Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial

Fawzy, Muhammad; Mesbah, Yasser

doi:10.1007/s00404-015-3755-5

Cited by 47 publications

(77 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We and other groups previously reported that dienogest is highly effective for pain associated with adenomyosis during 24 weeks or 16 weeks of treatment. A recent randomized, double blind, placebo‐controlled study also confirmed that dienogest is effective for pain due to adenomyosis during 16 weeks .…”

Section: Discussionmentioning

confidence: 72%

“…Dienogest, a novel 19‐nortestosterone derivative, is a synthetic oral progestin that is highly selective for progesterone receptors. Previous studies reported that dienogest is highly effective in reducing adenomyosis‐related pain . Dienogest is generally well tolerated; however, massive metrorrhagia is a major reason for discontinuing treatment with dienogest …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term dienogest administration in patients with symptomatic adenomyosis

Neriishi

Hirata

Fukuda

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Long‐term dienogest administration in patients with symptomatic adenomyosis

Neriishi

Hirata

Fukuda

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Thus, the health and daily activities of patients with severe AM may be greatly affected by the disease. Recent research has indicated that the incidence of AM is closely associated with ovarian hormone secretion (5,6). Under the influence of ovarian hormones, ectopic endometrial tissues undergo periodical changes and induce pathological changes of the metastatic sites, resulting in chronic pelvic pain and infertility (7,8).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the current study was to evaluate the expression of microRNA (miR)-17 in the endometrial tissues of patients with adenomyosis (AM) and determine its biological function in the occurrence and development of the disease. A total of 45 fresh endometrial tissues of AM patients and 32 normal endometrial tissues were collected from healthy controls. The expression of miR-17 was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The miR-17-targeting gene phosphatase and tensin homolog (PTEN) was predicted using bioinformatics and its expression was evaluated with RT-qPCR and western blot analysis. Endometrial cells were isolated from patients with AM and healthy controls. They were cultured in vitro and transfected with antagomiR-17 to downregulate miR-17 expression, subsequently cell viability and apoptosis were measured using MTT and flow cytometry. The expression of PTEN and cell cycle-and apoptosis-related proteins were evaluated using western blot analysis. Endometrial cells that stably overexpressed PTEN were screened in vitro by co-culture with G418. A dual-luciferase reporter assay was conducted to verify whether miR-17 was directly bound to PTEN mRNA. The results demonstrated that expression of miR-17 was significantly increased in the endometrial tissues of patients with AM compared with control patients (P<0.05). PTEN mRNA and protein expression were significantly lower in the AM group compared with the control group (P<0.05). When the expression of miR-17 in the cells was downregulated, the expression of PTEN was significantly increased (P<0.05). In addition, expression of Bcl-2 protein was significantly decreased and that of Bax protein significantly increased compared with the negative control (both P<0.05). The expression of cyclins E1 and D1 were also significantly downregulated (P<0.05). When PTEN was overexpressed or miR-17 was downregulated, the viability of endometrial cells significantly decreased and cell apoptosis significantly increased (all P<0.05). A dual-luciferase reporter assay indicated that miR-17 could directly bind to the PTEN mRNA 3'-untranslated region to regulate its expression. Thus the current study indicates that expression of miR-17 was increased in the endometrial tissues of patients with AM and may influence cell apoptosis and cyclin expression through the targeted regulation of PTEN. These results suggest that miR-17 promotes the occurrence and development of AM.

show abstract

“…Another pilot study presented the results on the efficacy and safety of dienogest in the treatment of symptomatic adenomyosis. Dienogest significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 and CA 19-9 levels [20].…”

Section: Oral Dienogestmentioning

confidence: 87%

Adenomyosis

Zheng¹,

Deng²

2021

Endometriosis

View full text Add to dashboard Cite

Adenomyosis is a benign uterus disease in which the invasion of the endometrial glands and/or stroma within myometrium is found and usually appears between the ages of 40 and 50 years in women. There are several differences in their pathogenesis. The secondary dysmenorrhea and menorrhagia are the common symptoms. Ultrasound sonography, MRI, CA125, and histological examination can be helpful for the diagnosis of adenomyosis. The treatment of adenomyosis depends on the patient's age, symptoms, and desire for future fertility, including medical treatment and surgical treatment.

show abstract

Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial

Abstract: Dienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis.

Cited by 47 publications

References 30 publications

Long‐term dienogest administration in patients with symptomatic adenomyosis

Long‐term dienogest administration in patients with symptomatic adenomyosis

MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis

Adenomyosis

Contact Info

Product

Resources

About